163 related articles for article (PubMed ID: 37453187)
21. Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use.
Syed YY
Clin Drug Investig; 2023 May; 43(5):369-377. PubMed ID: 37133675
[TBL] [Abstract][Full Text] [Related]
22. Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy.
Jones SA; McGovern M; Lidove O; Giugliani R; Mistry PK; Dionisi-Vici C; Munoz-Rojas MV; Nalysnyk L; Schecter AD; Wasserstein M
Mol Genet Metab; 2020; 131(1-2):116-123. PubMed ID: 32616389
[TBL] [Abstract][Full Text] [Related]
23. Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims Analysis.
Pulikottil-Jacob R; Ganz ML; Fournier M; Petruski-Ivleva N
Adv Ther; 2023 May; 40(5):2234-2248. PubMed ID: 36897522
[TBL] [Abstract][Full Text] [Related]
24. Autopsy pathology of infantile neurovisceral ASMD (Niemann-Pick Disease type A): Clinicopathologic correlations of a case report.
Thurberg BL
Mol Genet Metab Rep; 2020 Sep; 24():100626. PubMed ID: 32714837
[TBL] [Abstract][Full Text] [Related]
25. The impact of biomarkers analysis in the diagnosis of Niemann-Pick C disease and acid sphingomyelinase deficiency.
Deodato F; Boenzi S; Taurisano R; Semeraro M; Sacchetti E; Carrozzo R; Dionisi-Vici C
Clin Chim Acta; 2018 Nov; 486():387-394. PubMed ID: 30153451
[TBL] [Abstract][Full Text] [Related]
26. Real-life impacts of olipudase alfa: The experience of patients and families taking an enzyme replacement therapy for acid sphingomyelinase deficiency.
Raebel EM; Wiseman S; Donnelly C; Mathieson T; Pountney J; Crowe J; Hopkin J
Orphanet J Rare Dis; 2024 Feb; 19(1):36. PubMed ID: 38303068
[TBL] [Abstract][Full Text] [Related]
27. Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann-Pick disease types A, B and A/B).
Geberhiwot T; Wasserstein M; Wanninayake S; Bolton SC; Dardis A; Lehman A; Lidove O; Dawson C; Giugliani R; Imrie J; Hopkin J; Green J; de Vicente Corbeira D; Madathil S; Mengel E; Ezgü F; Pettazzoni M; Sjouke B; Hollak C; Vanier MT; McGovern M; Schuchman E
Orphanet J Rare Dis; 2023 Apr; 18(1):85. PubMed ID: 37069638
[TBL] [Abstract][Full Text] [Related]
28. Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.
Wasserstein MP; Jones SA; Soran H; Diaz GA; Lippa N; Thurberg BL; Culm-Merdek K; Shamiyeh E; Inguilizian H; Cox GF; Puga AC
Mol Genet Metab; 2015; 116(1-2):88-97. PubMed ID: 26049896
[TBL] [Abstract][Full Text] [Related]
29. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD).
McGovern MM; Avetisyan R; Sanson BJ; Lidove O
Orphanet J Rare Dis; 2017 Feb; 12(1):41. PubMed ID: 28228103
[TBL] [Abstract][Full Text] [Related]
30. Acid Sphingomyelinase Deficiency: Sharing Experience of Disease Monitoring and Severity in France.
Mauhin W; Borie R; Dalbies F; Douillard C; Guffon N; Lavigne C; Lidove O; Brassier A
J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207195
[TBL] [Abstract][Full Text] [Related]
31. Plasma chitotriosidase and CCL18: early biochemical surrogate markers in type B Niemann-Pick disease.
Brinkman J; Wijburg FA; Hollak CE; Groener JE; Verhoek M; Scheij S; Aten J; Boot RG; Aerts JM
J Inherit Metab Dis; 2005; 28(1):13-20. PubMed ID: 15702402
[TBL] [Abstract][Full Text] [Related]
32. Renal involvement in a patient with the chronic visceral subtype of acid sphingomyelinase deficiency resembles Fabry disease.
Eskes ECB; van der Lienden MJC; Roelofs JJTH; Vogt L; Aerts JMFG; Aten J; Hollak CEM
JIMD Rep; 2021 Nov; 62(1):15-21. PubMed ID: 34765393
[TBL] [Abstract][Full Text] [Related]
33. Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults.
Lachmann RH; Diaz GA; Wasserstein MP; Armstrong NM; Yarramaneni A; Kim Y; Kumar M
Orphanet J Rare Dis; 2023 Apr; 18(1):94. PubMed ID: 37098529
[TBL] [Abstract][Full Text] [Related]
34. Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective.
Pokrzywinski R; Hareendran A; Nalysnyk L; Cowie S; Crowe J; Hopkin J; Joshi D; Pulikottil-Jacob R
Sci Rep; 2021 Oct; 11(1):20972. PubMed ID: 34697402
[TBL] [Abstract][Full Text] [Related]
35. Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency.
Thurberg BL; Wasserstein MP; Jones SA; Schiano TD; Cox GF; Puga AC
Am J Surg Pathol; 2016 Sep; 40(9):1232-42. PubMed ID: 27340749
[TBL] [Abstract][Full Text] [Related]
36. Utility of amniotic fluid chitotriosidase in the prenatal diagnosis of lysosomal storage disorders.
Kadali S; Madalasa T; Reddy GM; Naushad SM
Clin Biochem; 2018 Nov; 61():40-44. PubMed ID: 30205089
[TBL] [Abstract][Full Text] [Related]
37. Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months.
Wasserstein MP; Diaz GA; Lachmann RH; Jouvin MH; Nandy I; Ji AJ; Puga AC
J Inherit Metab Dis; 2018 Sep; 41(5):829-838. PubMed ID: 29305734
[TBL] [Abstract][Full Text] [Related]
38. Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment.
Thurberg BL; Diaz GA; Lachmann RH; Schiano T; Wasserstein MP; Ji AJ; Zaher A; Peterschmitt MJ
Mol Genet Metab; 2020; 131(1-2):245-252. PubMed ID: 32620536
[TBL] [Abstract][Full Text] [Related]
39. Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial.
Wasserstein MP; Lachmann R; Hollak C; Barbato A; Gallagher RC; Giugliani R; Guelbert NB; Hennermann JB; Ikezoe T; Lidove O; Mabe P; Mengel E; Scarpa M; Senates E; Tchan M; Villarrubia J; Thurberg BL; Yarramaneni A; Armstrong NM; Kim Y; Kumar M
Orphanet J Rare Dis; 2023 Dec; 18(1):378. PubMed ID: 38042851
[TBL] [Abstract][Full Text] [Related]
40. LC-MS/MS analysis of plasma glucosylsphingosine as a biomarker for diagnosis and follow-up monitoring in Gaucher disease in the Spanish population.
Irún P; Cebolla JJ; López de Frutos L; De Castro-Orós I; Roca-Espiau M; Giraldo P
Clin Chem Lab Med; 2020 Apr; 58(5):798-809. PubMed ID: 32126008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
